AtriCure Crecimiento futuro
Future controles de criterios 3/6
Se prevé un crecimiento anual de los beneficios y los ingresos de AtriCure de 51% y 11% por año respectivamente. Se prevé que el BPA crezca en un 51.9% al año. Se espera que la rentabilidad financiera sea de 4.1% en 3 años.
Información clave
51.0%
Tasa de crecimiento de los beneficios
51.89%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Medical Equipment | 16.1% |
| Tasa de crecimiento de los ingresos | 11.0% |
| Rentabilidad financiera futura | 4.09% |
| Cobertura de analistas | Good |
| Última actualización | 13 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Artículo de análisis • Nov 01
AtriCure, Inc. (NASDAQ:ATRC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
AtriCure, Inc. ( NASDAQ:ATRC ) defied analyst predictions to release its quarterly results, which were ahead of market...Artículo de análisis • Aug 01
AtriCure, Inc. (NASDAQ:ATRC) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
AtriCure, Inc. ( NASDAQ:ATRC ) investors will be delighted, with the company turning in some strong numbers with its...Recent updates
Actualización de narrativa • May 19
ATRC: Product Moat And Clinical Data Will Support Bullish Repricing
Analysts have trimmed their fair value estimate for AtriCure to $55 from $64, reflecting updated assumptions for slightly softer revenue growth, a modestly lower profit margin outlook, and a reduced future P/E multiple, even as recent research points to ongoing product progress and a still supportive view from several firms despite rising competitive concerns. Analyst Commentary Recent research on AtriCure highlights a split in views, with some firms flagging competitive threats and others pointing to ongoing execution in sales, earnings, and product development as support for current valuations.
Actualización de narrativa • May 01
ATRC: Clinical Strength And 2026 Profitability Are Expected To Offset New Competition
The updated analyst price target for AtriCure now reflects a modest valuation reset in the mid to high $50 range, as analysts weigh recent target cuts and rating downgrades against ongoing confidence in the company's product pipeline, clinical data strength, and prospects for durable revenue growth with improving profitability. Analyst Commentary Recent research has introduced a mix of optimism and caution around AtriCure, with bullish views on the product portfolio and clinical positioning sitting alongside fresh concerns about competition and long term growth durability.Actualización de narrativa • Apr 17
ATRC: Clinical Moat And 2026 Profitability Are Expected To Withstand New Entrant
Narrative Update on AtriCure The updated analyst price target for AtriCure has edged down by about $0.23, reflecting a slightly higher discount rate and lower expected future P/E. Analysts are weighing new competitive risks against continued confidence in the company’s product pipeline, clinical data, and profitability progress.Actualización de narrativa • Apr 02
ATRC: 2026 Guidance And Clinical Moat Are Expected To Outlast New Competition
Analysts have modestly reduced the AtriCure price target by $1.31 to $36.41. This reflects both lower published Street targets in response to emerging competition and continued confidence in revenue growth, margins, and the company’s clinical and product positioning.Actualización de narrativa • Mar 19
ATRC: 2026 Guidance And Clinical Moat Will Confront Emerging Competition
Analysts have trimmed AtriCure's average price target by a few dollars to around the mid $50s. This reflects a mix of confidence in recent sales and EPS outperformance and product progress, tempered by concerns about emerging competition in left atrial appendage closure products and long term growth risks.Actualización de narrativa • Mar 04
ATRC: 2026 Guidance And New Dual Energy Platform Will Shape Upside
Analysts have adjusted their outlook on AtriCure, with our updated fair value estimate moving from $36.00 to about $37.72. This change reflects a mix of lower Street price targets, concerns about emerging competition, and continued confidence in the company’s product progress, clinical data, and profitability trajectory.Actualización de narrativa • Feb 18
ATRC: JPMorgan Downgrade And 2026 Profit Outlook Will Shape Risk Balance
Analysts have revised their AtriCure price target from $40.00 to $36.00, citing updated assumptions around discount rates, revenue growth, profit margins, and elevated future P/E expectations in light of recent research, including the JPMorgan downgrade. Analyst Commentary Recent commentary points to a more cautious stance on AtriCure, with the revised US$36.00 target reflecting what bearish analysts see as a need to factor in higher risk around execution, profitability, and future growth expectations.
Actualización de narrativa • Feb 04
ATRC: Dual Energy Platform Trial Progress Will Support Long Term Upside Potential
Analysts have adjusted their price targets on AtriCure, reflecting updated assumptions around discount rates, revenue growth, profit margins and a revised future P/E of 134.36x. Collectively, these factors support a fair value estimate of about $52.78 per share.Actualización de narrativa • Jan 21
ATRC: Future Trial Progress Will Drive Confidence In Long Term Outlook
AtriCure's updated analyst price target has increased from US$50.00 to about US$52.78. Analysts cite adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the key drivers of this change.Actualización de narrativa • Jan 06
ATRC: Dual Energy Ablation Breakthrough Will Drive Bullish Repricing
Analysts have maintained their price target on AtriCure at US$64.00, citing updated assumptions for slightly higher revenue growth, wider profit margins, a modestly higher discount rate, and a lower future P/E multiple as key inputs to their valuation work. What's in the News AtriCure announced successful first in human procedures using its dual energy platform that combines Pulsed Field Ablation with Advanced Radiofrequency Ablation, performed at Victorian Heart Hospital in Australia under Monash Health HREC approval (Key Developments).Actualización de narrativa • Dec 15
ATRC: Dual Energy Platform And Noaf Trial Will Drive Bullish Repricing
Analysts have raised their price target on AtriCure by approximately 7 percent to 64 dollars per share, reflecting greater confidence in the company’s improving profit margin outlook and more favorable long term valuation assumptions, despite a slightly higher discount rate. What's in the News AtriCure reported successful first in human procedures with its dual energy ablation platform that combines Pulsed Field Ablation with Advanced Radiofrequency Ablation, achieving box lesion creation and pulmonary vein plus posterior wall isolation in under 60 seconds in the first two patients (company announcement).Artículo de análisis • Dec 11
AtriCure, Inc.'s (NASDAQ:ATRC) 29% Share Price Surge Not Quite Adding Up
AtriCure, Inc. ( NASDAQ:ATRC ) shares have had a really impressive month, gaining 29% after a shaky period beforehand...Artículo de análisis • Nov 01
AtriCure, Inc. (NASDAQ:ATRC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
AtriCure, Inc. ( NASDAQ:ATRC ) defied analyst predictions to release its quarterly results, which were ahead of market...Artículo de análisis • Aug 01
AtriCure, Inc. (NASDAQ:ATRC) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
AtriCure, Inc. ( NASDAQ:ATRC ) investors will be delighted, with the company turning in some strong numbers with its...Artículo de análisis • Jul 08
AtriCure (NASDAQ:ATRC) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jun 26
AtriCure: Profits And Operating Leverage Are Needed Here
Summary AtriCure has had impressive and sound growth over the past decade. The company has continued to post losses, even though relative losses are coming down. The combination of double-digit sales growth and a 3 times sales multiple looks compelling, yet further margin gains are required to drive appeal here. Read the full article on Seeking AlphaArtículo de análisis • May 01
AtriCure, Inc. (NASDAQ:ATRC) Screens Well But There Might Be A Catch
It's not a stretch to say that AtriCure, Inc.'s ( NASDAQ:ATRC ) price-to-sales (or "P/S") ratio of 3.1x seems quite...Artículo de análisis • Apr 04
Is AtriCure (NASDAQ:ATRC) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Nueva narrativa • Mar 22
cryoSPHERE+ And EnCompass Clamp Launches Will Accelerate Global Adoption
New product launches and international expansion, especially in Europe and China, are key drivers for AtriCure's projected revenue growth and market leadership.Artículo de análisis • Jan 22
Revenues Tell The Story For AtriCure, Inc. (NASDAQ:ATRC) As Its Stock Soars 29%
AtriCure, Inc. ( NASDAQ:ATRC ) shares have continued their recent momentum with a 29% gain in the last month alone...Artículo de análisis • Jan 15
Calculating The Fair Value Of AtriCure, Inc. (NASDAQ:ATRC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, AtriCure fair value estimate is US$35.69 With US$34.69 share...Artículo de análisis • Dec 24
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Artículo de análisis • Nov 06
A Piece Of The Puzzle Missing From AtriCure, Inc.'s (NASDAQ:ATRC) 28% Share Price Climb
Despite an already strong run, AtriCure, Inc. ( NASDAQ:ATRC ) shares have been powering on, with a gain of 28% in the...Artículo de análisis • Nov 01
US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results
AtriCure, Inc. ( NASDAQ:ATRC ) defied analyst predictions to release its third-quarter results, which were ahead of...Artículo de análisis • Oct 31
Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?
AtriCure, Inc. ( NASDAQ:ATRC ), is not the largest company out there, but it saw a significant share price rise of 71...Artículo de análisis • Oct 02
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 43% Above Its Share Price
Key Insights AtriCure's estimated fair value is US$39.81 based on 2 Stage Free Cash Flow to Equity Current share price...Artículo de análisis • Sep 06
Further Upside For AtriCure, Inc. (NASDAQ:ATRC) Shares Could Introduce Price Risks After 29% Bounce
AtriCure, Inc. ( NASDAQ:ATRC ) shareholders would be excited to see that the share price has had a great month, posting...Artículo de análisis • Aug 02
Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report
There's been a notable change in appetite for AtriCure, Inc. ( NASDAQ:ATRC ) shares in the week since its...Seeking Alpha • Jul 25
AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care
Summary AtriCure, Inc. is a market leader in surgical solutions for atrial fibrillation, LAA management, and post-operative pain management, serving 2,000 hospitals globally. AtriCure's latest project involves expanding into the European market with innovative products, facing potential regulatory delays and market acceptance challenges. Despite facing competition from major players like Johnson & Johnson and Medtronic, AtriCure's strong revenue growth and innovative product lineup position it for continued success in the market. Read the full article on Seeking AlphaArtículo de análisis • Jul 18
AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward
AtriCure, Inc. ( NASDAQ:ATRC ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...Artículo de análisis • May 30
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, AtriCure fair value estimate is US$40.72 AtriCure's US$21.61...Artículo de análisis • Apr 04
Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump
AtriCure, Inc. ( NASDAQ:ATRC ) shareholders won't be pleased to see that the share price has had a very rough month...Artículo de análisis • Mar 14
Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Jan 21
Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues
When close to half the companies in the Medical Equipment industry in the United States have price-to-sales ratios (or...Artículo de análisis • Nov 29
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Sep 27
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price
Key Insights AtriCure's estimated fair value is US$84.48 based on 2 Stage Free Cash Flow to Equity Current share price...Artículo de análisis • Aug 02
Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Jun 15
AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion
AtriCure, Inc.'s ( NASDAQ:ATRC ) price-to-sales (or "P/S") ratio of 6.6x might make it look like a strong sell right...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 763 | 31 | N/A | 115 | 6 |
| 12/31/2027 | 678 | 17 | 41 | 94 | 9 |
| 12/31/2026 | 605 | 3 | 54 | 67 | 9 |
| 3/31/2026 | 552 | -5 | 48 | 64 | N/A |
| 12/31/2025 | 535 | -11 | 42 | 57 | N/A |
| 9/30/2025 | 518 | -29 | 16 | 43 | N/A |
| 6/30/2025 | 500 | -36 | 8 | 36 | N/A |
| 3/31/2025 | 480 | -38 | -1 | 22 | N/A |
| 12/31/2024 | 465 | -45 | -11 | 12 | N/A |
| 9/30/2024 | 448 | -39 | -1 | 10 | N/A |
| 6/30/2024 | 430 | -40 | -20 | -8 | N/A |
| 3/31/2024 | 415 | -37 | -55 | -12 | N/A |
| 12/31/2023 | 399 | -30 | -38 | 4 | N/A |
| 9/30/2023 | 381 | -25 | -43 | 1 | N/A |
| 6/30/2023 | 366 | -28 | -48 | -3 | N/A |
| 3/31/2023 | 349 | -38 | -18 | -2 | N/A |
| 12/31/2022 | 330 | -46 | -39 | -22 | N/A |
| 9/30/2022 | 316 | -56 | -37 | -22 | N/A |
| 6/30/2022 | 303 | 53 | -32 | -20 | N/A |
| 3/31/2022 | 290 | 52 | -41 | -29 | N/A |
| 12/31/2021 | 274 | 50 | -24 | -14 | N/A |
| 9/30/2021 | 259 | 45 | -18 | -10 | N/A |
| 6/30/2021 | 243 | -57 | -14 | -6 | N/A |
| 3/31/2021 | 213 | -49 | -18 | -13 | N/A |
| 12/31/2020 | 207 | -48 | -25 | -20 | N/A |
| 9/30/2020 | 210 | -46 | -36 | -27 | N/A |
| 6/30/2020 | 212 | -50 | -44 | -34 | N/A |
| 3/31/2020 | 230 | -46 | -31 | -18 | N/A |
| 12/31/2019 | 231 | -35 | N/A | -16 | N/A |
| 9/30/2019 | 222 | -23 | N/A | -11 | N/A |
| 6/30/2019 | 216 | -20 | N/A | -3 | N/A |
| 3/31/2019 | 209 | -17 | N/A | -8 | N/A |
| 12/31/2018 | 202 | -21 | N/A | -4 | N/A |
| 9/30/2018 | 195 | -20 | N/A | -4 | N/A |
| 6/30/2018 | 187 | -20 | N/A | -9 | N/A |
| 3/31/2018 | 180 | -27 | N/A | -9 | N/A |
| 12/31/2017 | 175 | -27 | N/A | -9 | N/A |
| 9/30/2017 | 170 | -33 | N/A | -10 | N/A |
| 6/30/2017 | 166 | -32 | N/A | -9 | N/A |
| 3/31/2017 | 160 | -34 | N/A | -14 | N/A |
| 12/31/2016 | 155 | -33 | N/A | -15 | N/A |
| 9/30/2016 | 150 | -36 | N/A | -20 | N/A |
| 6/30/2016 | 143 | -35 | N/A | -18 | N/A |
| 3/31/2016 | 135 | -32 | N/A | -10 | N/A |
| 12/31/2015 | 129 | -27 | N/A | -8 | N/A |
| 9/30/2015 | 123 | -22 | N/A | -6 | N/A |
| 6/30/2015 | 118 | -16 | N/A | -10 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que ATRC sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que ATRC sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que ATRC sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (11% al año) de ATRC crezcan más despacio que el mercado de US (11.9% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 11% al año) de ATRC crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de ATRC sea baja dentro de 3 años (4.1%).
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/27 14:16 |
| Precio de las acciones al final del día | 2026/05/27 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
AtriCure, Inc. está cubierta por 18 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Charley Jones | Barrington Research Associates, Inc. |
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |